primary antibodies in 0.1% PBST and incubated overnight at 4 o C, thereafter secondary antibodies in 0.1% PBST were added and cells were incubated for 1 h at room temperature. To-Pro iodide was used to stain DNA. For high content microscopy, 5000 cells per well were seeded in 96 well sanjiv et al plates and processed as described above. Cells were imaged using a PerkinElmer operetta high content microscope. Images from confocal microscopy were quantified manually using ImageJ software (more than 100 cells per condition). Columbus software was used to analyses images from the PerkinElmer operetta high content microscope (more than 500 cells).
Plasmid vector construction. PB-GFP plasmid (pHULK piggyBac Mammalian Expression
Vector -CometGFP™, pJ503-02) and PB-RFP plasmid (pHULK piggyBac Mammalian
Expression Vector -RudolphRFP™-IRES-CometGFP™, pJ549-17) were purchased from DNA2.0. PB-GFP-cMYC plasmid was generated as follows: cMYC DNA was amplified from pPB-CAG-cMYC (Wang et al., 2011) and was cloned into XbaI/BamhI sites of the PB-RFP plasmid (RFP gene was replaced with cMYC gene). The final product (PB-GFP-cMYC) was confirmed by DNA sequencing.
Generation of cell lines. HA1EB-GFP (control cells) and HA1EB-GFP-cMYC (cMYC overexpressing cells) were generated by stable transfection with PB-GFP or PB-GFP-cMYC, respectively. The respective plasmids were transfected into HA1EB cells using JetPEI® (101-10N, Polyplus-transfection). 1.5 million HA1EB cells were seeded into 75-cm 2 tissue culture flask. When cells were 70% confluent, they were transfected with 5 µg DNA and 10 µL JetPEI® for 4 hours. Thereafter, the medium was changed and cells were expanded for 7 days before their selection. Fluorescence Activated Cell Sorting (FACS) was used to select GFP positive cells. Viability assay and drug interaction. 1000-3000 cells per well were seeded into 96 well plates and incubated overnight. The next day, the cells were treated with vehicle DMSO (maximum 0.05%) or various concentrations of VE-821 and/or AZD7762. After 72 h of incubation, resazurin was added to each well and further incubated for 2-6 h. Fluorescence intensity was measured at 530/590 nm (excitation/ emission) (Gad et al., 2014) . DNA fibers were spread and stained as described previously (Groth et al., 2010) . In summary, cells were lysed and DNA spread on glass slides. Acid treated DNA was stained with primary antibodies (mouse anti-BrdU pure, clone B44, BD Biosciences; rat anti-BrdU, Batch No.0412, AbD Serotec) for 1 hour at 37°C and secondary antibodies (goat anti-rat AlexaFlour555; goat antimouse AlexaFluor488) for 2,5 hours at room temperature (Groth et al., 2010) . Pictures were taken with a Zeiss LSM-780 confocal microscope using the 63x oil objective. Fiber lengths were analysed using ImageJ software (http://rsb.info.nih.gov/ij/) and micrometer measurements were recalculated to kilobases with the conversion factor 1 μM = 1.59 kb (Henry-Mowatt et al., 2003) .
A minimum of 450 fibers was measured per condition. Roscovitine significantly increases the U2OS cell survival against combination of AZD7762/VE-821. U2OS cells were treated with the indicated drug concentrations for 72 h and viability was measure using resazurin. Quantitative data, mean ± S.E.M. from 4 independent experiments. Statistical significance was determined using Student's t-test. *p<0.05; **p<0.01, ***p<0.001. (C) CDK /CDC7inhibitor PHA-767491 reduce the pan-nuclear γH2AX and 53BP1 foci in U2OS cells cotreated with VE-821 and AZD7762. U2OS cells were pretreated with PHA-
